Morningside Group

Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.

HQShanghai, CN
Cybersecurity ratingCMore
Morningside Group was founded in 1986 and is headquartered in Shanghai, CN

Viewing summary data as a guest

Sign up for free to see all data

Morningside Group Office Locations

Morningside Group has an office in Shanghai
Show all (1)

Morningside Group Online and Social Media Presence

Embed Graph

Morningside Group Blogs

Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

TOKYO and NANJING, China, Dec. 18, 2020 /PRNewswire/ — Teijin Pharma Limited (“Teijin Pharma”), the core company of the Teijin Group’s healthcare business headquartered in Tokyo, Japan, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China…

Additional Analyses of Efficacy and Safety of Pridopidine for Huntington’s Disease Demonstrate Positive Effect on Functional Capacity

— Positive results from additional analyses of PRIDE-HD and Open-HART trials with pridopidine published in peer-reviewed journal, The Journal of Huntington’s Disease. — Exploratory additional efficacy data show pridopidine (45 mg bid) to be the first drug to exert a significant and clinically meanin…

Everlywell Announces $175 Million Financing to Expand Consumer Lab Testing and Digital Health Offerings

The investment will help accelerate Everlywell’s mission to transform consumer diagnostics AUSTIN, Texas, Dec. 3, 2020 /PRNewswire/ — Everlywell, a leading digital health company, today announced an oversubscribed Series D financing of $175 million. New investors participating in the round include f…

Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis

— BT051, a gut-restricted drug which is designed to target neutrophil migration and subsequent activation, was shown to be safe and well tolerated. CONCORD, Mass. (BUSINESS WIRE) — Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced …

Tallac Therapeutics Launches With $62M Run by ALX Oncology Vets, With an Eye on Next-Gen Cancer

Ben Adams Fierce Biotech December 1, 2020 A host of top-suite venture capitalist firms has helped put together a meaty series A for an immuno-oncology biotech 2.0. Californian startup Tallac Therapeutics has $62 million and the backing of venBio Partners, Morningside Venture, Lightstone Ventures, Ma…

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

U.S. (US Fed News) — registry received information related to the study (NCT04635995) titled ‘Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy’ on Nov. 9. LVGN7409 is a humanized monoclonal antibody th…
Show more

Morningside Group Frequently Asked Questions

  • When was Morningside Group founded?

    Morningside Group was founded in 1986.

  • Where are Morningside Group offices?

    Morningside Group has an office in Shanghai.

  • How many offices does Morningside Group have?

    Morningside Group has 1 office.